Device Trial Radar · NCT05902065
Effect of a Progressive Treadmill Training Protocol for Parkinson's Disease
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Jul 6, 2022
Primary completion
Sep 18, 2024
Study completion Dec 16, 2024
Sponsor
- Lead sponsor
- University of FlorenceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fondazione Don Carlo Gnocchi ETS
- First posted
- Jun 13, 2023
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this single-center, no-profit, longitudinal interventional randomized controlled, single-blind trial is to compare the effects of 2 different treadmill training treatments using C-Mill: the experimental one, endowed with augmented virtual reality (AVR) applications, versus the conventional one, the standard treadmill training in PD patients with gait and or balance disturbances. The main questions the study aims to answer are 1) Is the experimental treatment more effective than the conventional one? 2) Is it possible to identify predictive and indicative biomarkers of an outcome measure of rehabilitation using extracellular vesicles (cEVs) assessed by Raman spectroscopy? Participants will be randomized into two groups: the experimental group that will receive the experimental intervention, and the control group that will receive the conventional intervention. Both groups will train three times per week for 8 weeks, the first session starting from 25 minutes (25'). The experimental and the conventional treatments are planned to be progressive and will be individualized to the participant's level of performance. Clinical, neuropsychological, and instrumental variables will be collected at baseline (T0), at the end of the treatment (T1), and 3 months after the end of treatment (T2). At 6 months after the end of treatment (T3), a phone interview will be performed. Both within-group and between-group analyses will be conducted. Biosamples will be collected at baseline (T0) and at the end of treatment (T1).
Conditions
- Parkinson Disease
- Gait, Festinating
- Fall Due to Loss of Equilibrium
- Gait, Unsteady
- Gait, Shuffling
Interventions
AVR Treadmill training with C-MillDevice
The protocol will include three sessions per week for 8 weeks of gait training using C-Mill with AVR applications. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. The patient will be supervised by a physical therapist and asked not to use lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance. Progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'; progression in difficulty: the protocol has 5 levels for each AVR application, and the transition among levels will be set at 80% success achievement.
Conventional Treadmill training with C-MillDevice
The protocol will include three sessions per week for 8 weeks of gait training using C-Mill without AVR applications, walking on the treadmill. An anchoring system will prevent possible falls, activities will be stopped on patient request, or when a heart rate considered safe will be exceeded. All sessions will be supervised by a physical therapist, who will give guidance and standardized cues on walking patterns (e.g., step length). The patient will be asked not to use the lateral bars. Treatment is planned to be progressive and will be individualized to the participant's level of performance: progression in gait speed: at the training start, gait speed will be set at 80% of the individual's overground walking speed and weekly increased by 10%, to a maximum of 120%; progression in trial duration: at the training start the duration will be set at 25' and every two weeks increased by 5'; the maximum duration of a session will reach 45'.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in gait and balance parameters assessed by the Performance Oriented Mobility Assessment - POMA scale (intra-group and between-group comparisons)Time frame: T0 (baseline); T1 (end of the treatment - 8 weeks); T2 (3 months after the end of treatment)
- Mean change in motors parameters assessed by the Modified Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III (intra-group and between-group comparisons)Time frame: T0 (baseline); T1 (end of the treatment - 8 weeks); T2 (3 months after the end of treatment)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
IRCCS Fondazione Don Gnocchi Firenze
Florence, Florence, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.